nutrients-logo

Journal Browser

Journal Browser

Nutrition in Liver Diseases and Transplantation

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Clinical Nutrition".

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 2441

Special Issue Editor


E-Mail Website
Guest Editor
Department of Emergency and Organ Transplantation, University of Bari "Aldo Moro", 70124 Bari, Italy
Interests: liver transplantation; gastrointestinal diseases; hepatocellular carcinoma; cirrhosis

Special Issue Information

Dear Colleagues,

The liver is not only the organ deputed to the transient storage, distribution, and metabolism of all our nutritional fonts but synthetizes several molecules that are indispensable in our body and is also the only organ responsible for the clearance of some end products that, if accumulated in the case of hepatic dysfunction, become life-threatening. At the same time, its pivotal role with respect to nutritional intake makes the liver particularly susceptible to dietary manipulations.

Currently, due to the important socio-economic impact of non-alcoholic fatty liver diseases, and particularly of non-alcoholic steatohepatitis, a large number of publications have focused on this issue; however, patients’ demand for precise nutritional indications to be adopted in case of other liver diseases other than compensated or decompensated cirrhosis remains high.

For this Special Issue, we invite articles (original articles or reviews) related to the most suitable nutritional strategies for the treatment of the broad spectrum of pathological conditions involving the liver (acute hepatitis, chronic hepatitis, NASH-NAFLD (Nonalcoholic steatohepatitis-Nonalcoholic fatty liver disease), alcohol abuse, cirrhosis, decompensated cirrhosis, liver transplantation, biliary diseases, gallstones, malnutrition from other pathologies, liver disease during TPN (total parenteral nutrition)). It will be particularly interesting to include articles dealing with special dietary recommendations in liver-transplanted patients since their use of immunosuppressive drugs potentially induces sarcopenia. Moreover, the role of nutraceuticals, pre-and probiotics, as well as new theoretical nutritional approaches, for the cure of liver diseases is of great interest.

Prof. Dr. Michele Barone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Chronic Liver Disease
  • Liver Cirrhosis
  • Hepatic Insufficiency
  • Liver Decompensation
  • Ascites
  • Hepatic Encephalopathy
  • NAFDL
  • NASH
  • Post-Transplant Obesity
  • Post-transplant NASH
  • Acute Liver Rejection
  • Hepatic Cholestasis
  • Post-Cholecystectomy Diarrhea

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 789 KiB  
Article
Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV
by Cristiane Fonseca de Almeida, Paula Simplicio da Silva, Claudia Santos de Aguiar Cardoso, Nathalia Gorni Moreira, Julliana Cormack Antunes, Michelle Morata de Andrade, Julio Silva, Marina Campos Araujo, Wilza Arantes Ferreira Peres, Pedro Emmanuel Alvarenga Americano do Brasil, Ronaldo Ismerio Moreira, Sandra W. Cardoso, Valdilea G. Veloso, Beatriz Grinsztejn, Patricia Dias de Brito and Hugo Perazzo
Nutrients 2021, 13(10), 3462; https://0-doi-org.brum.beds.ac.uk/10.3390/nu13103462 - 29 Sep 2021
Cited by 8 | Viewed by 1947
Abstract
We aimed to evaluate the relationship between food intake of lipids with nonalcoholic fatty liver disease (NAFLD) and/or liver fibrosis in people living with HIV/AIDS (PLWHA). In this cross-sectional study, transient elastography was used to detect the presence of NAFLD and/or liver fibrosis. [...] Read more.
We aimed to evaluate the relationship between food intake of lipids with nonalcoholic fatty liver disease (NAFLD) and/or liver fibrosis in people living with HIV/AIDS (PLWHA). In this cross-sectional study, transient elastography was used to detect the presence of NAFLD and/or liver fibrosis. The dietary intake of fats and fatty acids (FA) were assessed by two 24 h dietary recalls (24-HDR) (n = 451). Multivariate logistic regression models were performed. Participants with higher intake of total fat were associated with higher odds for NAFLD compared to those with lower consumption [adjusted odds ratio (aOR) = 1.91 (95% confidence interval (95% CI) 1.06–3.44)]. Furthermore, participants with intermediate intake of n6-PUFA (n6-poly-unsaturated FA) and lauric FA had lower odds for NAFLD, respectively aOR = 0.54 (95% CI 0.3–0.98) and aOR = 0.42 (95% CI 0.22–0.78). Additionally, a higher intake of myristoleic FA (fourth quartile) was a significant protective factor for NAFLD [aOR = 0.56 (95% CI 0.32–0.99)]. Participants with higher intake of lauric FA [0.38 (95% CI 0.18–0.80)], myristic FA [0.38 (0.17–0.89)], palmitoleic FA [0.40 (0.19–0.82)] and oleic FA [0.35 (0.16–0.79)] had positively less odds of having liver fibrosis. On the other hand, higher intake of n-6 PUFA was significantly associated with fibrosis [aOR = 2.45 (95% CI 1.12–5.32)]. Dietary assessment of total fat and FA should be incorporated into HIV care as a tool for preventing NAFLD and fibrosis in PLWHA. Full article
(This article belongs to the Special Issue Nutrition in Liver Diseases and Transplantation)
Show Figures

Figure 1

Back to TopTop